European Union - English - EMA (European Medicines Agency)

menarini international operations luxembourg s.a. (miol) - ranolazine - angina pectoris - cardiac therapy - ranexa is indicated as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line anti-anginal therapies (such as beta-blockers and / or calcium antagonists).,

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a. menarini farmaceutica internazionale srl - ranolazine - modified-release tablet - 500mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a. menarini farmaceutica internazionale srl - ranolazine - modified-release tablet - 375mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a. menarini farmaceutica internazionale srl - ranolazine - modified-release tablet - 750mg

Singapore - English - HSA (Health Sciences Authority)

a. menarini singapore pte. ltd. - ranolazine - tablet, film coated, extended release - ranolazine 375 mg

Singapore - English - HSA (Health Sciences Authority)

a. menarini singapore pte. ltd. - ranolazine - tablet, film coated, extended release - ranolazine 500 mg

Singapore - English - HSA (Health Sciences Authority)

a. menarini singapore pte. ltd. - ranolazine - tablet, film coated, extended release - ranolazine 750 mg

Ireland - English - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - ranolazine - prolonged-release tablet - ranolazine

Ireland - English - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - ranolazine - prolonged-release tablet - ranolazine

Ireland - English - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - ranolazine - prolonged-release tablet - ranolazine